Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times ...
Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent ...
Predictors of attrition in the treatment of metastatic colorectal cancer (MCRC). Neuroendocrine tumor (NET) patient (pt) experience with disease management: Results from the first global NET pt survey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback